IQVIA’s second quarter was characterized by broad-based growth and accelerating demand across its clinical and commercial businesses, with market participants responding positively to the results. CEO Ari Bousbib attributed the strong performance to improved operational execution and a healthier demand environment, highlighting a 6% organic growth rate—triple that of last year. Management also cited strong net new bookings and increasing win rates, particularly in the R&D segment, as contributing factors to the quarter’s outperformance.
Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).
IQVIA (IQV) Q2 CY2026 Highlights:
- Revenue: $4.37 billion vs analyst estimates of $4.30 billion (8.7% year-on-year growth, 1.5% beat)
- Adjusted EPS: $3.15 vs analyst estimates of $3.03 (3.9% beat)
- Adjusted EBITDA: $994 million vs analyst estimates of $964.1 million (22.8% margin, 3.1% beat)
- The company slightly lifted its revenue guidance for the full year to $17.38 billion at the midpoint from $17.25 billion
- Management slightly raised its full-year Adjusted EPS guidance to $12.90 at the midpoint
- EBITDA guidance for the full year is $4.03 billion at the midpoint, in line with analyst expectations
- Operating Margin: 11.6%, down from 12.6% in the same quarter last year
- Constant Currency Revenue rose 8.5% year on year (3.6% in the same quarter last year)
- Market Capitalization: $38.41 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From IQVIA’s Q2 Earnings Call
- Eric Coldwell (Baird) asked if any large, unusual awards contributed to bookings strength; CEO Ari Bousbib replied that results were broad-based with no abnormal items, stating, “there is absolutely nothing salient, unusual, abnormal, odd, untoward in our numbers.”
- Justin Bowers (Deutsche Bank) inquired about outsourcing penetration trends; Bousbib explained large pharma clients are expanding outsourcing due to AI, with some requesting IQVIA to expand capacity for anticipated study growth.
- Michael Ryskin (Bank of America) questioned future AI and M&A investment; Bousbib emphasized proprietary data and domain expertise as advantages, noting collaborations with all major AI companies and co-development agreements with four of the top ten pharma clients.
- David Windley (Jefferies) probed the impact of recent acquisitions and expansion into discovery; Bousbib confirmed the Charles River deal’s contribution and signaled ongoing expansion up and down the service chain.
- Jailendra Singh (Truist Securities) asked about margin improvement drivers and AI’s productivity impact; CFO Michael J. Fedock attributed margin gains to operational productivity programs, with AI as a supporting lever.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will monitor (1) the pace of new bookings and backlog quality in R&D Solutions, (2) further adoption and monetization of AI-enabled offerings across both clinical and commercial segments, and (3) integration of recent acquisitions like the Charles River assets. Progress on operational productivity programs and clarity on potential adjustments to inactive trials in the backlog will also be important to track.
IQVIA currently trades at $233.40, up from $213.22 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
